In clinical practice, both IHC(3+) and IHC(2+)/FISH(+) tumors are treated as HER2-positive breast cancer, which is also the case for some new HER2-targeted drugs, such as pertuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.